{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:43:33Z","timestamp":1793043813361,"version":"4.5.0"},"reference-count":52,"publisher":"American Chemical Society (ACS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2014,6,2]]},"DOI":"10.1021\/mp500070m","type":"journal-article","created":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T12:50:18Z","timestamp":1396011018000},"page":"1739-1749","source":"Crossref","is-referenced-by-count":92,"title":["Making the Leap from Daily Oral Dosing to Long-Acting Injectables: Lessons from the Antipsychotics"],"prefix":"10.1021","volume":"11","author":[{"given":"Julius F.","family":"Remenar","sequence":"first","affiliation":[{"name":"Alkermes, plc, 852 Winter Street, Waltham, Massachusetts 02451-1420, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2014,4,30]]},"reference":[{"issue":"6","key":"ref1\/cit1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/COH.0000000000000002","volume":"8","author":"Spreen W. R.","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"3","key":"ref2\/cit2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejpb.2009.03.006","volume":"72","author":"Baert L.","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref3\/cit3","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2147\/PPA.S53795","volume":"7","author":"Kaplan G.","year":"2013","journal-title":"Patient Preference and Adherence"},{"key":"ref4\/cit4","unstructured":"Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations[Online]. U.S. Department of Health and Human Servies, U.S. Food & Drug Administration Website.http:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/default.cfm(accessed Mar 19, 2014) ."},{"key":"ref5\/cit5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-244X-10-45","volume":"10","author":"McDonnell D. P.","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"2","key":"ref6\/cit6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/00000542-200408000-00029","volume":"101","author":"Woo Y. C.","year":"2004","journal-title":"Anesthesiology"},{"key":"ref7\/cit7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/B978-0-12-397220-0.00008-8","volume":"37","author":"Germann D.","year":"2012","journal-title":"Profiles Drug Subst., Excipients, Relat. Methodol."},{"key":"ref8\/cit8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/B978-0-12-407691-4.00002-2","volume":"38","author":"Ardiana F.","year":"2013","journal-title":"Profiles Drug Subst., Excipients, Relat. Methodol."},{"issue":"3","key":"ref9\/cit9","first-page":"377","volume":"1","author":"Srinivasa rao N.","year":"2012","journal-title":"Int. J. Clin. Pract."},{"issue":"12","key":"ref10\/cit10","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1002\/jps.22205","volume":"99","author":"Stella V. J.","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref11\/cit11","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-49785-3","volume-title":"Prodrugs: Challenges and Rewards. Part 2","volume":"5","author":"Stella V. J.","year":"2007"},{"key":"ref12\/cit12","volume-title":"Compendium of Chemical Terminology","author":"IUPAC","year":"1997","edition":"2"},{"key":"ref13\/cit13","unstructured":"New Drug Product Exclusivity. Code of Federal Regulation, Part 314.108(a), Title 21, 2013."},{"issue":"10","key":"ref14\/cit14","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/0006-2952(87)90058-X","volume":"36","author":"Nambu K.","year":"1987","journal-title":"Biochem. Pharmacol."},{"issue":"37","key":"ref15\/cit15","doi-asserted-by":"crossref","first-page":"16270","DOI":"10.1039\/c3ra41967c","volume":"3","author":"Blumberg L. C.","year":"2013","journal-title":"RSC Adv."},{"key":"ref16\/cit16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-397220-0.00001-5","volume":"37","author":"Brittain H. G.","year":"2012","journal-title":"Profiles Drug Subst., Excipients, Relat. Methodol."},{"issue":"11","key":"ref17\/cit17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.2042-7158.2010.01022.x","volume":"62","author":"Peltonen L.","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"ref18\/cit18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0928-0987(02)00251-8","volume":"18","author":"Merisko-Liversidge E.","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref19\/cit19","first-page":"325","volume-title":"Pharmaceutical Preformulation and Formulation","author":"Broadhead J.","year":"2009","edition":"2"},{"issue":"2","key":"ref20\/cit20","first-page":"60","volume":"14","author":"Koo O. M. Y.","year":"2011","journal-title":"Am. Pharm. Rev."},{"key":"ref21\/cit21","unstructured":"Guidance on the Administration to Adults of Oil Based Depot and other Long-Acting Intramuscular Antipsychotic Injections [online],3rd ed.Feetam, C.; White, J., Eds.; 2011; available atwww.hull.ac.uk\/injectionguide(accessed September 15, 2013) ."},{"key":"ref22\/cit22","unstructured":"Francois, M. K. J.; Embrechts, R. C. A.; Borghijs, H. K.; Monbaliu, J.Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters. Patent publication WO 1997\/044039, May 12, 1997."},{"key":"ref23\/cit23","unstructured":"Mesens, J. L.; Peeters, J.Risperidone Pamoate. Patent publication WO 1994\/25460 A1, Nov 10, 1994."},{"issue":"1","key":"ref24\/cit24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0378-5173(83)90125-4","volume":"16","author":"Howard J. R.","year":"1983","journal-title":"Int. J. Pharm."},{"issue":"2","key":"ref25\/cit25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1248\/cpb.29.519","volume":"29","author":"Hirano K.","year":"1981","journal-title":"Chem. Pharm. Bull."},{"issue":"1","key":"ref26\/cit26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0928-0987(94)00070-G","volume":"3","author":"Huang Y.","year":"1995","journal-title":"Eur. J. Pharm. Sci."},{"issue":"9","key":"ref27\/cit27","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1023\/A:1011978327504","volume":"15","author":"Luo J. P.","year":"1998","journal-title":"Pharm. Res."},{"issue":"3","key":"ref28\/cit28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF03189894","volume":"12","author":"Matsunaga Y.","year":"1987","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"8","key":"ref29\/cit29","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1023\/A:1012165731390","volume":"14","author":"Luo J. P.","year":"1997","journal-title":"Pharm. Res."},{"issue":"5","key":"ref30\/cit30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1600-0773.1979.tb02404.x","volume":"45","author":"Svendsen O.","year":"1979","journal-title":"Acta Pharmacol. Toxicol."},{"issue":"10","key":"ref31\/cit31","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1248\/cpb.23.2232","volume":"23","author":"Nakamoto Y.","year":"1975","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"ref32\/cit32","unstructured":"Remenar, J. F.; Blumberg, L. C.; Zeidan, T. A.Lactam derivatives as prodrugs for the treatment of neurological and psychiatric disorders, their preparation and drug delivery systems. WO 2010\/151689 A1, Dec 29, 2010."},{"issue":"11","key":"ref33\/cit33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1248\/bpb1978.14.615","volume":"14","author":"Oh-e Y.","year":"1991","journal-title":"J. Pharmacobiodyn."},{"key":"ref34\/cit34","unstructured":"Florence, A. T.; Vezin, W. R.Prolongation of the action of intramuscular formulations of phenothiazines. InOptimization of Drug Delivery; Proceedings of theAlfred Benzon Symposium 17, Copenhagen, May 31\u2013June 4, 1981;Bundgaard, H.; Hanse, A. B.; Kofod, H., Eds.Munksgaard:Copenhagen, 1982; pp93\u2013113."},{"issue":"1","key":"ref35\/cit35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v12.i1.10","volume":"12","author":"Okada H.","year":"1995","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"ref36\/cit36","unstructured":"Petersen, H.Poly(lactide-co-glycolide)s: technical requirements for processing this biodegradable copolymers into parenteral depots. In Pharmaceutical Polymers 2007, Conference Proceedings, Basil, Switzerland, June 20\u201321, 2007;Smithers Rapra Ltd.:Shawbury, U.K., 2007; paper 16, pp1\u20136."},{"key":"ref37\/cit37","unstructured":"Rickey, M. E.; Ramstack, J. M.; Lewis, D. H.; Mesens, J.Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent. U.S. Patent 5,792,477A, Aug 11, 1998."},{"key":"ref38\/cit38","unstructured":"Lyons, S. L.; Ramstack, M. J.; Wright, S. G.Preparation of microparticles having a selected release profile. U.S. Patent U.S. 6,379,703 B1, Apr 30, 2002."},{"issue":"4","key":"ref39\/cit39","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1208\/s12249-012-9874-4","volume":"13","author":"Selmin F.","year":"2012","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"ref40\/cit40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/02652040802396575","volume":"26","author":"Dunne M. M.","year":"2009","journal-title":"J. Microencapsulation"},{"issue":"3","key":"ref41\/cit41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jconrel.2007.05.034","volume":"122","author":"Zolnik B. S.","year":"2007","journal-title":"J. Controlled Release"},{"issue":"6","key":"ref42\/cit42","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/02652040802033913","volume":"25","author":"Nahata T.","year":"2008","journal-title":"J. Microencapsulation"},{"key":"ref43\/cit43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-0-387-25842-3_2","volume-title":"BioMEMS and Biomedical Nanotechnology","volume":"1","author":"Kim K.","year":"2006"},{"key":"ref44\/cit44","unstructured":"Brown, J.Methods for administering aripiprazole. U.S. Patent U.S. 8,338,427 B2, Dec 25, 2012."},{"issue":"2","key":"ref45\/cit45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1742-1241.2009.02240.x","volume":"64","author":"Citrome L.","year":"2009","journal-title":"Int. J. Clin. Pract."},{"key":"ref46\/cit46","unstructured":"Kostanski, J. W.; Matsuda, T.; Nerurkar, M.; Naringrekar, V. H.Controlled release sterile injectable suspension of aripiprazole for treatment of schizophrenia. U.S. Patent U.S. 8,030,313 B2, OCT 4, 2011."},{"key":"ref47\/cit47","unstructured":"Francois, M. K. J.; Dries, W. M. A. C.; Basstanie, E. D. G.Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters. U.S. Patent U.S. 6,555,544 B2, APR 29, 2003."},{"key":"ref48\/cit48","unstructured":"Remenar, J. F.; Almarsson, O.; Wood, M.; Waters, J.; Zeidan, T. A.; Sanrame, C.; Blumberg, L. C.LinkeRx: A versatile platform for designing prodrugs forextendedrelease after intramuscular administration. Abstract of poster presented at the 40th Annual Meeting of the Controlled Release Society [Online], Honolulu, July 21\u201324, 2013; 100854. Controlled Release Society Website.http:\/\/www.controlledreleasesociety.org\/meetings\/Documents\/2013Abstracts\/100854.pdf(accessed Mar 19, 2014) ."},{"key":"ref49\/cit49","unstructured":"Stokbroekx, S.Formulation effects on drug absorption. Presented at Bioavailability and Bioequivalence: Focus of Physiological Factors and Variability-EUFEPS and COST B25, Athens, Greece, Oct 1\u20132, 2007;http:\/\/www.docstoc.com\/docs\/92592226\/Formulation-Effects-on-Drug-Absorption(accessed Mar 19, 2014) ."},{"key":"ref50\/cit50","unstructured":"Darville, N.; Van Heerden, M.; Vynckier, A.; Sterkens, P.; Annaert, P.; Van den Mooter, G.Insights into the local inflammatory reaction induced by intramuscular injection of sustained-release drug microsuspensions. Abstract of poster presented at the 40th Annual Meeting of the Controlled Release Society [Online], Honolulu, July 21\u201324, 2013; 100549. Controlled Release Society Website.http:\/\/www.controlledreleasesociety.org\/meetings\/Documents\/2013Abstracts\/100549.pdf(accessed Mar 19, 2014) ."},{"key":"ref51\/cit51","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1308-4"},{"issue":"1","key":"ref52\/cit52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/157488611794480070","volume":"6","author":"Alphs L.","year":"2011","journal-title":"Curr. Drug Saf."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/mp500070m","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T18:12:04Z","timestamp":1682619124000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/mp500070m"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,30]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6,2]]}},"alternative-id":["10.1021\/mp500070m"],"URL":"https:\/\/doi.org\/10.1021\/mp500070m","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,30]]}}}